Treats overactive bladder with symptoms of urge urinary incontinence, urgency and…. ANDA 207664, held by Cipla. Darifenacin Hydrobromide.
As of Nov 16, 2026, ANDA 207664 (Darifenacin Hydrobromide), held by Cipla, was first approved by FDA on Sep 1, 2016, with 1 approved supplement and 0 published complete response letters.
Darifenacin extended-release tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 1, 2016 | Original application | Approved | None posted |
| Darifenacin HydrobromideEQ 7.5MG BASE · tablet, extended release;oral | Darifenacin Hydrobromide | Rx |
| Darifenacin HydrobromideEQ 15MG BASE · tablet, extended release;oral | Darifenacin Hydrobromide | Rx |
| Feb 18, 2022 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 1, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters